{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:00:35Z","timestamp":1781715635331,"version":"3.54.5"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202301AY070001-146"],"award-info":[{"award-number":["202301AY070001-146"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kunming University of Science and Technology, Basic Research Program","award":["KUST-PE2022004Y"],"award-info":[{"award-number":["KUST-PE2022004Y"]}]},{"name":"Pu 'er city Science and Technology Program project","award":["PEKJ2023003Z"],"award-info":[{"award-number":["PEKJ2023003Z"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Oridonin, a tetracyclic diterpenoid from\n                    <jats:italic>Rabdosia rubescens (Hemsl.) Hara,<\/jats:italic>\n                    exhibits various pharmacological actions, such as anti-tumor, anti-infective, and anti-inflammatory properties. However, the underlying pharmacological effects of oridonin on triple-negative breast cancer (TNBC) are yet to be elucidated. This study aims to examine the molecular mechanism and pharmacological impact of oridonin on TNBC using a network pharmacological strategy. Initially, the pharmacological databases and analysis platforms were employed to identify the potential targets of oridonin using the GeneCards website. The process of standardizing gene names involved the conversion of all target genes using the UniProt database. The acquired data was subjected to identify prevalent target genes. Then, these genes were examined using the STRING website to create a protein-protein interaction (PPI) network. In addition to Gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, a molecular docking analysis was conducted to validate the binding conformation between oridonin and the putative target genes. Among the selected 549 genes, 106 genes were found to interact with TNBC. The KEGG study suggested that the underlying mechanism could potentially be linked to the PI3K\/Akt signaling pathway and proteoglycans in cancer. Moreover, molecular docking studies indicated that oridonin exhibited the strongest binding affinity with AKT1 (binding energy: \u221211.40 kcal\/mol) and significant associations with other major targets, including EGFR, NFKB1, MAPK1, and SRC. In summary, the resultant findings based on molecular docking and network pharmacology could demonstrate the potential applicability of oridonin for treating TNBC through pathways like PI3K\/Akt signaling.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0332697","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T18:33:50Z","timestamp":1764614030000},"page":"e0332697","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the mechanism of oridonin against triple-negative breast cancer based on network pharmacology and molecular docking"],"prefix":"10.1371","volume":"20","author":[{"given":"Yuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2412-2514","authenticated-orcid":true,"given":"Diping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"pone.0332697.ref001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"P Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"pone.0332697.ref002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"F Derakhshan","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"pone.0332697.ref003","doi-asserted-by":"crossref","first-page":"113249","DOI":"10.1016\/j.jep.2020.113249","article-title":"The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer","volume":"264","author":"Z Yang","year":"2021","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"pone.0332697.ref004","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-023-02702-4","article-title":"Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer","volume":"42","author":"F Zhou","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"pone.0332697.ref005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.gendis.2020.06.010","article-title":"Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance","volume":"8","author":"X Liu","year":"2020","journal-title":"Genes Dis"},{"key":"pone.0332697.ref006","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10495-021-01684-y","article-title":"Terpenoids\u2019 anti-cancer effects: focus on autophagy","volume":"26","author":"C El-Baba","year":"2021","journal-title":"Apoptosis"},{"issue":"2","key":"pone.0332697.ref007","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3892\/etm.2021.10318","article-title":"Oridonin improves the therapeutic effect of lentinan on lung cancer","volume":"22","author":"Y Gui","year":"2021","journal-title":"Exp Ther Med"},{"issue":"18","key":"pone.0332697.ref008","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/jcmm.17841","article-title":"Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha\/androgen receptor\/TGF-beta signalling pathway axis","volume":"27","author":"S Gao","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"4","key":"pone.0332697.ref009","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jsps.2017.04.037","article-title":"Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling","volume":"25","author":"S Xia","year":"2017","journal-title":"Saudi Pharm J"},{"issue":"6","key":"pone.0332697.ref010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/ijms.70733","article-title":"Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2\/STAT3 signaling","volume":"19","author":"W Liu","year":"2022","journal-title":"Int J Med Sci"},{"key":"pone.0332697.ref011","doi-asserted-by":"crossref","first-page":"4340950","DOI":"10.1155\/2021\/4340950","article-title":"Oridonin promotes apoptosis and restrains the viability and migration of bladder cancer by impeding TRPM7 expression via the ERK and AKT signaling pathways","volume":"2021","author":"X Che","year":"2021","journal-title":"Biomed Res Int"},{"issue":"2","key":"pone.0332697.ref012","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/diagnostics13020272","article-title":"Theranostics for triple-negative breast cancer","volume":"13","author":"H Choi","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"pone.0332697.ref013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10822-016-9915-2","article-title":"TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models","volume":"30","author":"Z-J Yao","year":"2016","journal-title":"J Comput Aided Mol Des"},{"issue":"2","key":"pone.0332697.ref014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/toxsci\/kfad069","article-title":"CTD tetramers: a new online tool that computationally links curated chemicals, genes, phenotypes, and diseases to inform molecular mechanisms for environmental health","volume":"195","author":"AP Davis","year":"2023","journal-title":"Toxicol Sci"},{"key":"pone.0332697.ref015","article-title":"Expansion of the Gene Ontology knowledgebase and resources","volume":"45","author":"The Gene Ontology C","journal-title":"Nucleic Acids Res"},{"key":"pone.0332697.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"M Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"50","key":"pone.0332697.ref017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023546","article-title":"Network pharmacology-based strategy for predicting therapy targets of Tripterygium wilfordii on acute myeloid leukemia","volume":"99","author":"T Fang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"pone.0332697.ref018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.canlet.2016.06.024","article-title":"A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5","volume":"380","author":"J Wu","year":"2016","journal-title":"Cancer Lett"},{"issue":"11","key":"pone.0332697.ref019","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1039\/D4MD00580E","article-title":"In vitro identification of oridonin hybrids as potential anti-TNBC agents inducing cell cycle arrest and apoptosis by regulation of p21, \u03b3H2AX and cleaved PARP","volume":"15","author":"J Ning","year":"2024","journal-title":"RSC Med Chem"},{"issue":"15","key":"pone.0332697.ref020","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1021\/acs.jmedchem.0c00408","article-title":"Identification of a potent oridonin analogue for treatment of triple-negative breast cancer","volume":"63","author":"H Yao","year":"2020","journal-title":"J Med Chem"},{"key":"pone.0332697.ref021","doi-asserted-by":"crossref","first-page":"106831","DOI":"10.1016\/j.intimp.2020.106831","article-title":"Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-\u03b2 receptor","volume":"88","author":"J Guo","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"pone.0332697.ref022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"M Martini","year":"2014","journal-title":"Ann Med"},{"issue":"1","key":"pone.0332697.ref023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-021-00248-2","article-title":"SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2","volume":"7","author":"GA Mehta","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"pone.0332697.ref024","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/biomedicines9070740","article-title":"PI3K and MAPK pathways as targets for combination with the Pan-HER irreversible inhibitor neratinib in HER2-positive breast cancer and TNBC by kinome RNAi Screening","volume":"9","author":"J Lee","year":"2021","journal-title":"Biomedicines"},{"key":"pone.0332697.ref025","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919897546","article-title":"Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer","volume":"12","author":"A Canonici","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"pone.0332697.ref026","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00432-017-2557-5","article-title":"Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR\/Integrin \u03b21\/ Src signaling in triple negative breast cancer cells","volume":"144","author":"Z Hamurcu","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"pone.0332697.ref027","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5603\/FHC.a2021.0029","article-title":"Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6\/MAPK signaling","volume":"59","author":"S Huang","year":"2021","journal-title":"Folia Histochem Cytobiol"},{"issue":"5","key":"pone.0332697.ref028","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-021-03680-1","article-title":"Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637\/Akt1\/\u03b2-catenin (cyclin D1) axis","volume":"12","author":"S-J Yang","year":"2021","journal-title":"Cell Death Dis"},{"issue":"1","key":"pone.0332697.ref029","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neo.2020.10.012","article-title":"Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3","volume":"23","author":"Z Zhu","year":"2021","journal-title":"Neoplasia"},{"issue":"10","key":"pone.0332697.ref030","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/febs.13627","article-title":"NFKB1: a suppressor of inflammation, ageing and cancer","volume":"283","author":"T Cartwright","year":"2016","journal-title":"FEBS J"},{"key":"pone.0332697.ref031","first-page":"357485","article-title":"Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis","volume":"2015","author":"L Zhang","year":"2015","journal-title":"Biomed Res Int"},{"issue":"13","key":"pone.0332697.ref032","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.7150\/thno.57706","article-title":"EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer","volume":"11","author":"X Liu","year":"2021","journal-title":"Theranostics"},{"issue":"3","key":"pone.0332697.ref033","doi-asserted-by":"crossref","first-page":"382","DOI":"10.33594\/000000027","article-title":"The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer","volume":"52","author":"Y Liu","year":"2019","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"pone.0332697.ref034","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","article-title":"MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling","volume":"13","author":"D Zimmerli","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"pone.0332697.ref035","article-title":"MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer","volume":"9","author":"S-Y Wu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"pone.0332697.ref036","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","article-title":"Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer","volume":"10","author":"K-M Lee","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"pone.0332697.ref037","doi-asserted-by":"crossref","first-page":"146969","DOI":"10.1016\/j.gene.2022.146969","article-title":"Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: a case-control study","volume":"851","author":"I Sghaier","year":"2023","journal-title":"Gene"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T18:33:57Z","timestamp":1764614037000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332697"}},"subtitle":[],"editor":[{"given":"Ruo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332697","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}